4CPS-181 Study of the reasons for the therapeutic discontinuation of immune-based therapies in relapsing-remitting multiple sclerosis

摘要

Nowadays, 12 different therapies are available as immune-mediated therapies (IMT) for multiple sclerosis (MS) drugs. Guidelines classify these treatments as first- and second-line. This variety allows treatment discontinuations (TD) under situations different from those initially planned. Apart from high disease activity or poor drug tolerance, patient comfort or lack of adherence are becoming important reasons for TD. Treatment changing reasons in the usual practice can help better understand this reality and in future decision making.